Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$47.68 USD
-2.22 (-4.45%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $47.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
IONS 47.68 -2.22(-4.45%)
Will IONS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IONS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IONS
How Should You Play AstraZeneca (AZN) After Q2 Beat, View Raise?
Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?
IONS: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog AstraZeneca, Ionis and Sanofi
Ionis (IONS) Q2 Earnings and Revenues Beat, Stock Rises
Ionis Pharmaceuticals (IONS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Other News for IONS
Alnylam: HELIOS-B Success Priced In Already
JPMorgan healthcare analysts hold an analyst/industry conference call
Truist biotech analysts hold an analyst/industry conference call
Ionis to present at upcoming investor conferences
What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticals